 |
- Home
- Clinical Perspectives
- Business Perspectives
- Patient Care
- CME
- Community
- Products
- Careers
- Contact Us
CMS passed a new rule in October mandating remuneration for office-based claims submitted for small intraocular doses of bevacizumab. The compensation amount was established using the average price of the drug plus 6%, the margin meant to cover a physician’s costs as a proficient provider, but it did not factor in compounding costs, which range from $15 to $45. Physicians wishing to be reimbursed retroactively for the Q2024 code must request it from their Medicare contractors. The Q2024 code will be effective until Dec. 31 for facility-based services. Afterward, hospitals should use C9257 for any ophthalmic use of bevacizumab, according to the AAO. | Featured Jobs Practice Tools Coding Counselor Simple and accurate ICD-9 code search. Start Here  Patient Education Print customized patient education handouts. Start Here  Dermatology Diagnosis Identify skin diseases by age, gender, location. Start Here  AHRQ Clinical Guidelines Objective findings on medical interventions. Start Here     |
